Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Children with levothyroxine (T21) have developmental delay and other functional gastrointestinal (GI) issues that may negatively affect L-T4 tolerability and absorption. For an age group unable to swallow tablets whole by mouth, tablets must be crushed and suspended in water, breast milk or formula for administration in order to treat children with hypothyroidism. For this age group, ease of administration may have a significant impact on compliance and ability to remain euthyroid. We propose that Tirosint-SOL® will be more favorably received due to ease of administration, improved tolerability and palatability, therefore leading to improved adherence when compared to L-T4 tablets.
Epistemonikos ID: 0e3cc9c42014007e1057a957ff455d8fd992bb9b
First added on: May 08, 2024